Preoperative concurrent chemo- and endocrine therapies for women with large operable breast cancer expressing steroid hormone receptors

Research output: Contribution to journalArticle

Abstract

Preoperative chemotherapy and endocrine therapy yielded low pathological complete remission (pCR) rates in patients with endocrine responsive breast cancer. Patients with large operable (cT2-T3, N0-2, M0), ER ≥10% breast cancer were treated in two consecutive studies with preoperative chemotherapy (Study I: six courses of either fluorouracil, leucovorin, vinorelbine (FLN), or vinorelbine, cisplatin, and continuous infusion of fluorouracil (ViFuP), at the discretion of the treating physician; Study II: capecitabine and oral vinorelbine (CAVINO)). Concurrent letrozole (in association with triptorelin if premenopause) was given. Sixty-five (58 evaluable) and 55 (all evaluable) patients were enrolled in the two studies. In Study I there were 43 objective responders (74%, 95% CI 63-85%), three of whom had pCR. Thirty-nine objective responses (91%) and all pCR were observed in patients with tumors expressing ER ≥50%. In Study II 34 patients (62%, 95% CI 49-75%) had an objective response. Endocrine therapy administered together with new intravenous, containing regimens should be explored in the preoperative treatment of endocrine responsive breast cancer.

Original languageEnglish
Pages (from-to)654-660
Number of pages7
JournalBreast
Volume17
Issue number6
DOIs
Publication statusPublished - Dec 2008

Fingerprint

Steroid Receptors
Hormones
Breast Neoplasms
letrozole
Fluorouracil
Premenopause
Triptorelin Pamoate
Therapeutics
Drug Therapy
Leucovorin
Cisplatin
Physicians
vinorelbine
Neoplasms

Keywords

  • Breast cancer
  • Chemoendocrine therapy
  • Predictive factors
  • Primary therapy

ASJC Scopus subject areas

  • Surgery

Cite this

@article{c93eda8a76fb4b008daffb95d8e9a051,
title = "Preoperative concurrent chemo- and endocrine therapies for women with large operable breast cancer expressing steroid hormone receptors",
abstract = "Preoperative chemotherapy and endocrine therapy yielded low pathological complete remission (pCR) rates in patients with endocrine responsive breast cancer. Patients with large operable (cT2-T3, N0-2, M0), ER ≥10{\%} breast cancer were treated in two consecutive studies with preoperative chemotherapy (Study I: six courses of either fluorouracil, leucovorin, vinorelbine (FLN), or vinorelbine, cisplatin, and continuous infusion of fluorouracil (ViFuP), at the discretion of the treating physician; Study II: capecitabine and oral vinorelbine (CAVINO)). Concurrent letrozole (in association with triptorelin if premenopause) was given. Sixty-five (58 evaluable) and 55 (all evaluable) patients were enrolled in the two studies. In Study I there were 43 objective responders (74{\%}, 95{\%} CI 63-85{\%}), three of whom had pCR. Thirty-nine objective responses (91{\%}) and all pCR were observed in patients with tumors expressing ER ≥50{\%}. In Study II 34 patients (62{\%}, 95{\%} CI 49-75{\%}) had an objective response. Endocrine therapy administered together with new intravenous, containing regimens should be explored in the preoperative treatment of endocrine responsive breast cancer.",
keywords = "Breast cancer, Chemoendocrine therapy, Predictive factors, Primary therapy",
author = "Rosalba Torrisi and Silvia Dellapasqua and Raffaella Ghisini and Giuseppe Viale and Paolo Veronesi and Alberto Luini and Mattia Intra and Giulia Peruzzotti and Andrea Rocca and Alessandra Balduzzi and Anna Cardillo and Aron Goldhirsch and Marco Colleoni",
year = "2008",
month = "12",
doi = "10.1016/j.breast.2008.05.002",
language = "English",
volume = "17",
pages = "654--660",
journal = "Breast",
issn = "0960-9776",
publisher = "Churchill Livingstone",
number = "6",

}

TY - JOUR

T1 - Preoperative concurrent chemo- and endocrine therapies for women with large operable breast cancer expressing steroid hormone receptors

AU - Torrisi, Rosalba

AU - Dellapasqua, Silvia

AU - Ghisini, Raffaella

AU - Viale, Giuseppe

AU - Veronesi, Paolo

AU - Luini, Alberto

AU - Intra, Mattia

AU - Peruzzotti, Giulia

AU - Rocca, Andrea

AU - Balduzzi, Alessandra

AU - Cardillo, Anna

AU - Goldhirsch, Aron

AU - Colleoni, Marco

PY - 2008/12

Y1 - 2008/12

N2 - Preoperative chemotherapy and endocrine therapy yielded low pathological complete remission (pCR) rates in patients with endocrine responsive breast cancer. Patients with large operable (cT2-T3, N0-2, M0), ER ≥10% breast cancer were treated in two consecutive studies with preoperative chemotherapy (Study I: six courses of either fluorouracil, leucovorin, vinorelbine (FLN), or vinorelbine, cisplatin, and continuous infusion of fluorouracil (ViFuP), at the discretion of the treating physician; Study II: capecitabine and oral vinorelbine (CAVINO)). Concurrent letrozole (in association with triptorelin if premenopause) was given. Sixty-five (58 evaluable) and 55 (all evaluable) patients were enrolled in the two studies. In Study I there were 43 objective responders (74%, 95% CI 63-85%), three of whom had pCR. Thirty-nine objective responses (91%) and all pCR were observed in patients with tumors expressing ER ≥50%. In Study II 34 patients (62%, 95% CI 49-75%) had an objective response. Endocrine therapy administered together with new intravenous, containing regimens should be explored in the preoperative treatment of endocrine responsive breast cancer.

AB - Preoperative chemotherapy and endocrine therapy yielded low pathological complete remission (pCR) rates in patients with endocrine responsive breast cancer. Patients with large operable (cT2-T3, N0-2, M0), ER ≥10% breast cancer were treated in two consecutive studies with preoperative chemotherapy (Study I: six courses of either fluorouracil, leucovorin, vinorelbine (FLN), or vinorelbine, cisplatin, and continuous infusion of fluorouracil (ViFuP), at the discretion of the treating physician; Study II: capecitabine and oral vinorelbine (CAVINO)). Concurrent letrozole (in association with triptorelin if premenopause) was given. Sixty-five (58 evaluable) and 55 (all evaluable) patients were enrolled in the two studies. In Study I there were 43 objective responders (74%, 95% CI 63-85%), three of whom had pCR. Thirty-nine objective responses (91%) and all pCR were observed in patients with tumors expressing ER ≥50%. In Study II 34 patients (62%, 95% CI 49-75%) had an objective response. Endocrine therapy administered together with new intravenous, containing regimens should be explored in the preoperative treatment of endocrine responsive breast cancer.

KW - Breast cancer

KW - Chemoendocrine therapy

KW - Predictive factors

KW - Primary therapy

UR - http://www.scopus.com/inward/record.url?scp=56649102283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56649102283&partnerID=8YFLogxK

U2 - 10.1016/j.breast.2008.05.002

DO - 10.1016/j.breast.2008.05.002

M3 - Article

C2 - 18595702

AN - SCOPUS:56649102283

VL - 17

SP - 654

EP - 660

JO - Breast

JF - Breast

SN - 0960-9776

IS - 6

ER -